Gary Schiller, M.D.

Work Titles
UCLA Director, Bone Marrow/Stem Cell Transplantation Professor, Hematology-Oncology Member, JCCC Cancer and Stem Cell Biology Program Area Member, Oncology Treatment Center at UCLA Member, Therapeutic Hemapheresis Member, Transfusion Medicine & Blood Banking
M.D., USC School of Medicine, 1984
1987 - 1990 UCLA School of Medicine
1984 - 1985 UCLA School of Medicine
1985 - 1987 UCLA School of Medicine
1990 American Board of Internal Medicine
1989 American Board of Internal Medicine
1987 American Board of Internal Medicine

Contact Information:

Work Email Address:



Work Address:

42-121 CHS

Westwood, CA 90095

Detailed Biography:

Dr. Schiller is a well-published clnical investigator in acute and chronic leukemias, multiple myeloma, and other hematologic malignancies, as well as in stem cell and bone marrow transplantation. He lectures extensively, and has also written for the popular press. He is Immediate-Past Chairman of the Los Angeles Museum of the Holocaust. His research projects include clinical studies of new drugs, therapies, and bone marrow/stem cell transplantation for patients with malignancies of the blood or bone marrow such as leukemia, multiple myeloma, and lymphoma. He has carried out studies of stem cell transplantation following high-dose chemotherapy and radiation for acute myelogenous leukemia, one of the most common types of leukemia in adults. He has also carried out work with purified stem cell transplantation for multiple myeloma. He has ongoing studies using new drugs and therapeutics for acute and chronic lymphocytic leukemia, acute and chronic myelogenous leukemia, and multiple myeloma; he also has studies going on in certain kinds of non-Hodgkin's lymphoma and Sickle Cell Anemia. His approach is to put into clinical trials new treatments developed in the laboratory for patients with blood stem cell diseases or cancers of the bone marrow and blood.


A selected list of publications:

Schiller GJ, Slack J, Hainsworth JD, Mason J, Saleh M, Rizzieri D, Douer D, List AF.   Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes, J Clin Oncology, 2006; 24(2006 Jun 1): 2456-2464.
Lashkari A, Lowe T, Collisson E, Paquette R, Emmanouilides C, Territo M, Schiller G.   Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia, Biol Blood Marrow Transplant, 2006; 12(April 2006): 466-471.
Catenacci DV, Schiller GJ.   Myelodysplasic syndromes: a comprehensive review, Blood Reviews, 2005; 19(6): 301-319.
Lin MZ, Teitell MA, Schiller GJ   The evolution of antibodies into versatile tumor-targeting agents Clinical cancer research : an official journal of the American Association for Cancer Research. , 2005; 11(1): 129-38.
Emmanouilides C, Colovos C, Pinter-Brown L, Hernandez L, Schiller G, Territo M, Rosen P   Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma Clin Lymphoma, 2004; 5(1): 45-9.
Collisson EA, Lashkari A, Malone R, Paquette R, Emmanouilides C, Territo MC, Schiller GJ   Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. , 2003; 17(11): 2183-8.
Schiller GJ   Myelodysplasia--therapeutic response to novel therapy and the need for new diagnostic groups Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. , 2003; 17(6): 1183-5.
Levine JE, Harris RE, Loberiza FR, Armitage JO, Vose JM, Van Besien K, Lazarus HM, Horowitz MM, Bashey A, Bolwell BJ, Burns LJ, Cairo MS, Champlin RE, Freytes CO, Gibson J, Goldstein SC, Laughlin MJ, Lister J, Marks DI, Maziarz RT, Miller AM, Milone GA, Pavlovsky S, Pecora AL, Rizzo JD, Schiller G, Schouten HC, Zhang MJ   A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma Blood. , 2003; 101(7): 2476-82.
Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T   Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein Blood. , 2003; 101(7): 2461-3.

Does this profile need updating? Contact Us